IVIG To SCIG Transition denied as not medically necessary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for ivig to scig transition are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies the IVIG-to-SCIG Transition on Medical-Necessity Grounds

Blue Cross Blue Shield may deny a transition from intravenous immunoglobulin (IVIG) to subcutaneous immunoglobulin (SCIG) by concluding the change is a matter of convenience rather than clinical need — that IVIG is already working and SCIG is not medically necessary. This is one of the most winnable denial types because the clinical record almost always contains concrete, documentable reasons the transition serves the patient's medical interests: venous access deterioration, systemic reactions to IV infusion, quality-of-life impairment from infusion-center scheduling, or clinical evidence that SCIG produces more stable immunoglobulin levels for a particular patient.

## Why This Denial Is Appealable

Medical-necessity determinations are reviewable at every level. Under ACA §2719, external independent reviewers assess medical necessity against current clinical standards, not solely the plan's internal criteria. Under ERISA §503, employer-plan members are entitled to a full-and-fair review with access to the clinical rationale used in the denial. File internally within the timeframe on your EOB (usually 180 days). If internally denied, external review must typically be requested within 4 months. Expedited review is available when the standard timeline would seriously jeopardize health.

## The Concrete Appeal Process

1. Request the specific BCBS coverage policy and the clinical criteria used to deny; you have the right to receive the exact standard applied. 2. Have the prescribing specialist draft a detailed medical-necessity letter tied directly to those criteria. 3. Submit the internal appeal with supporting chart documentation. 4. If denied internally, proceed to independent external review.

## Documentation to Gather

• Diagnosis and severity: Current chart notes from the treating immunologist or specialist confirming the diagnosis and clinical status.
• IVIG treatment history: Dates of infusions, settings (infusion center vs. home), any adverse events or tolerability concerns, documented IgG trough levels over time.
• Clinical rationale for transition: Specific chart entries documenting the medical reason for switching — venous access notes, infusion reaction records, IVIG-related adverse effects, or evidence that consistent trough levels would improve clinical control.
• Prescriber medical-necessity letter: Explicitly addresses each criterion in the BCBS coverage policy and explains, with chart-referenced facts, why SCIG is medically necessary for this patient.
• Applicable guideline reference: A statement that the transition is consistent with the applicable professional society's guidance (do not cite numbers — cite the organization).

## Criteria-Mapping Structure

Download BCBS's current published medical/coverage policy for immunoglobulin therapy. Read every listed criterion. For each one, document the matching chart evidence:

| BCBS Policy Criterion | Supporting Chart Evidence | |---|---| | [Copy exact criterion] | [Chart note, date, specialist finding] | | [Copy exact criterion] | [Chart note, date, specialist finding] |

The prescriber's letter should mirror this table exactly. When reviewers see every criterion addressed point-by-point with specific chart citations, the appeal is far harder to sustain.